Title: Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Authors: Judson, Ian ×
Verweij, Jaap
Gelderblom, Hans
Hartmann, Jörg T
Schöffski, Patrick
Blay, Jean-Yves
Kerst, J Martijn
Sufliarsky, Josef
Whelan, Jeremy
Hohenberger, Peter
Krarup-Hansen, Anders
Alcindor, Thierry
Marreaud, Sandrine
Litière, Saskia
Hermans, Catherine
Fisher, Cyril
Hogendoorn, Pancras C W
Dei Tos, A Paolo
van der Graaf, Winette T A
for the European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group #
Issue Date: Apr-2014
Publisher: Lancet Pub. Group
Series Title: The Lancet Oncology vol:15 issue:4 pages:415-23
Article number: S1470-2045(14)70063-4
Abstract: Effective targeted treatment is unavailable for most sarcomas and doxorubicin and ifosfamide-which have been used to treat soft-tissue sarcoma for more than 30 years-still have an important role. Whether doxorubicin alone or the combination of doxorubicin and ifosfamide should be used routinely is still controversial. We assessed whether dose intensification of doxorubicin with ifosfamide improves survival of patients with advanced soft-tissue sarcoma compared with doxorubicin alone.
ISSN: 1470-2045
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science